| Drug Name |
Emtricitabine |
| Drug ID |
BADD_D00766 |
| Description |
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults[L9019] or combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and adults.[L9010] Emtricitabine is a cytidine analogue.[L9019] The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.[L9019]
Emtricitabine was granted FDA approval on 2 July 2003.[L9019] |
| Indications and Usage |
Indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and for postexposure prophylaxis of HIV infection in health care workers and others exposed occupationally or nonoccupationally via percutaneous injury or mucous membrane or nonintact skin contact with blood, tissues, or other body fluids associated with risk for transmission of the virus. |
| Marketing Status |
Prescription |
| ATC Code |
J05AF09 |
| DrugBank ID |
DB00879
|
| KEGG ID |
D01199
|
| MeSH ID |
D000068679
|
| PubChem ID |
60877
|
| TTD Drug ID |
D0S9SD
|
| NDC Product Code |
68554-0064; 70518-1847; 59997-0005; 42385-304; 72761-008; 69097-642; 52696-0008; 65862-305; 70518-2906; 42385-710; 49711-1516; 61958-0601; 69037-0003; 66721-400; 65015-838; 33342-500; 53104-7637; 68554-0027; 70966-0024; 65015-827; 61958-0602; 65015-883; 66406-0209 |
| Synonyms |
Emtricitabine | Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine | Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine | Coviracil | Emtriva |
